文献速递生殖医学

生殖医学临床试验中研究方案依从性与生物样本库参与的相关因素及其与活产的关系

Factors associated with study protocol adherence and bio banking participation in reproductive medicine clinical trials and their relationship to live birth.
PubMed 文献 · Hum Reprod · 2020-01-01

该研究对两项美国多中心双盲试验(PPCOS II 和 AMIGOS)的1650名参与者进行二次分析,发现种族、BMI和较低收入与生殖医学临床试验方案不依从的可能性相关,种族影响生物样本采集,且方案不依从与活产概率降低相关。

要点

  • 非裔或亚裔、较高BMI和较低家庭收入者更可能不依从研究方案。
  • 方案不依从与活产概率降低相关(OR 0.180, 95%CI 0.120-0.272, P<0.001)。
  • 非裔或亚裔参与可选DNA采集的可能性低于白人。

核心结论

  • 种族、BMI和较低收入与生殖医学临床试验方案不依从的可能性相关,方案不依从与活产概率降低相关。

研究设计与样本

  • 对来自两项前瞻性多中心双盲对照研究(PPCOS II和AMIGOS)的1650名参与者进行二次数据分析,研究在美国14个临床中心开展。

主要发现

  • 自我认同为非裔美国人或亚裔、较高BMI和较低家庭收入的女性更不可能依从方案。
  • 方案不依从与活产概率降低相关(OR 0.180, 95%CI 0.120-0.272, P<0.001)。
  • 非裔美国人或亚裔参与可选DNA采集的可能性低于白人。
  • 非裔美国人、高年收入、来自西南部站点或患有PCOS的参与者更不可能参与血液样本库研究。

临床怎么用

  • 识别参与度低的人群是重要第一步,后续可制定针对性措施以提高方案依从性和生物样本库参与度。

局限性

  • 种族和族裔为自我报告,可能不能始终代表整个种族或族裔群体。
  • 研究仅纳入两项美国多中心试验,结果可能无法外推至国际试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What demographic and baseline characteristics are predictive of adherence to reproductive medicine clinical trial protocols, live birth or participation in genetic studies? SUMMARY ANSWER: Race, BMI and lower income are associated with likelihood of non-adherent to reproductive medicine clinical trial protocols, while race influences collection of biological samples and non-adherent to study protocols is associated with lower probability of live birth. WHAT IS KNOWN ALREADY: Although aspects of adherence to study protocol have previously been evaluated as individual factors in infertile women, the factors that affect overall non-adherent to study protocol have not been previously evaluated. STUDY DESIGN, SIZE, DURATION: A secondary data analysis of 1650 participants from two prospective multicenter, double-blind controlled studies was carried out: Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) and Assessment of Multiple Intrauterine Gestations from Ovarian Stimulation (AMIGOS). PARTICIPANTS/MATERIALS, SETTING, METHODS: The participants were women aged 18-40 years old with either polycystic ovary syndrome (PCOS) with ovulatory dysfunction in combination with either hyperandrogenemia and/or polycystic ovarian morphology (PPCOS II), or regular ovulatory cycles with unexplained infertility (AMIGOS). The study was carried out in 14 clinical sites in the USA. Non-adherence to clinical trial protocol was chosen as the primary outcome for this analysis. To evaluate whether demographic and baseline characteristics were predictive of adherence to study protocols, live birth or participation in blood sampling for DNA and repository, and pregnancy registry, these putative factors were compared between the outcome measures. Logistic regression was used to establish a prediction model using the putative predictors introduced above. MAIN RESULTS AND THE ROLE OF CHANCE: Women who self-identified as African American or Asian and those with higher BMI and lower household income were less likely to adhere to protocol. Non-adherence to the study protocol was associated with a lower probability of live birth (odds ratio: 0.180, 95% CI: 0.120, 0.272, P < 0.001). African Americans or Asians were less likely to participate in optional study DNA collection compared to Whites. Participants who were African American or with high annual income or from the Southwest sites or had PCOS were less likely to participate in the blood repository studies. LIMITATIONS, REASONS FOR CAUTION: Race and ethnicity were self-reported and such self-classification to strict race and ethnicity may not always be representative of a whole racial or ethnic group. This study included two US multicenter trials and therefore the findings may not be extrapolated to international trials. WIDER IMPLICATIONS OF THE FINDINGS: Identification of populations with low participation is an important initial step, as further investigation can develop specific measures to improve adherence to study protocols and participation in biospecimen banking and thereby extend the representativeness of reproductive medicine clinical trial findings. STUDY FUNDING/COMPETING INTEREST(S): Supported by NIH Eunice Kennedy Shriver NICHD Grants: U10 HD39005, U10 HD38992, U10 HD27049, U10 HD38998, U10 HD055942, HD055944, U10 HD055936, U10HD055925, PPCOSII: U10 HD27049, U10 HD38992, U10 HD055925, U10 HD39005, U10 HD38998, U10 HD055936, U10 HD055942, U10 HD055944; Clinical Reproductive Endocrine Scientist Training Program (CREST): R25HD075737. Outside this study, M.P.D. received NIH/NIHCD research grant and R.S.L. received research grant from Ferring and was consultant for Bayer, Kindex, Odega, Millendo and AbbVie. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov number: NCT00719186; NCT01044862.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Engmann L, Sun F, Legro RS, et al. Factors associated with study protocol adherence and bio banking participation in reproductive medicine clinical trials and their relationship to live birth. Hum Reprod. 2020. PMID: 33190149. doi:10.1093/humrep/deaa232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。